Cargando…

Reactivation of hepatitis B (reverse seroconversion) after melphalan/dexamethasone therapy for primary amyloidosis: a case report

INTRODUCTION: Hepatitis B virus (HBV) reactivation (so-called reverse seroconversion) is a rare but known complication of hematopoietic stem cell transplantation, immunosuppressive therapy, or high-dose chemotherapy plus rituximab. This event is linked to a treatment-related fall in titers of antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moon, Woo-Ram, Moon, Do-Sik, Kim, JoA, Yoon, Young-min, Choi, Byung-Seok, Chung, Choon-Hae, Park, Sang-Gon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460636/ https://www.ncbi.nlm.nih.gov/pubmed/26031455 http://dx.doi.org/10.1186/s13256-015-0610-z

Ejemplares similares

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?
por: Zhao, Hao, et al.
Publicado: (2019)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up
por: Hegenbart, Ute, et al.
Publicado: (2017)

Pathologic improvement after high-dose melphalan and autologous stem cell transplantation for primary systemic amyloidosis
por: Hoshino, Junichi, et al.
Publicado: (2008)

Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2020)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

Pulmonary amyloidosis and multiple myeloma mimicking lymphoma in a patient with Sjogren’s syndrome: A case report
por: Kim, Joa, et al.
Publicado: (2022)

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis
por: Liebers, Nora, et al.
Publicado: (2022)

Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma
por: Lee, Seung-Shin, et al.
Publicado: (2019)

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
por: Landau, H, et al.
Publicado: (2017)

Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
por: Brennan, Xavier, et al.
Publicado: (2022)

Hepatic amyloidosis
por: Shin, Yong Moon
Publicado: (2011)

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells
por: Gillardin, Pierre-Samuel, et al.
Publicado: (2017)

The Seroconversion Rate of Hepatitis A Virus Vaccination among Patients with Hepatitis B Virus-Related Chronic Liver Disease in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2011)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Dexamethasone to the rescue
por: Moon, Chang
Publicado: (2020)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Cutaneous and Systemic Plasmacytosis Associated with Renal Amyloidosis
por: Lee, Taek Geun, et al.
Publicado: (2015)

Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum
por: Lee, Hee-Jeong, et al.
Publicado: (2014)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

Single Nodular Pulmonary Amyloidosis: Case Report
por: Lee, Seung Hyun, et al.
Publicado: (2015)

Isolated Tricuspid Regurgitation: Initial Manifestation of Cardiac Amyloidosis
por: Yoon, Dong Woog, et al.
Publicado: (2015)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

First Case of Nodular Localized Primary Cutaneous Amyloidosis Treated With Bortezomib and Dexamethasone
por: Khan, Noman Ahmed Jang, et al.
Publicado: (2021)

Retracted: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Incidence of Infection among Subjects with Helicobacter pylori Seroconversion
por: Kim, Young Jung, et al.
Publicado: (2022)

The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.
por: Honess, D. J., et al.
Publicado: (1985)

The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
por: Hinchliffe, M., et al.
Publicado: (1983)

Oral Melphalan Therapy in Advanced Malignant Disease
por: Clifford, Peter, et al.
Publicado: (1963)

Nitric oxide enhancement of melphalan-induced cytotoxicity.
por: Cook, J. A., et al.
Publicado: (1997)

Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice
por: Shah, Nisha V., et al.
Publicado: (2014)

Intravitreal Melphalan Chemotherapy for Vitreous Seeds in Retinoblastoma
por: Yousef, Yacoub A., et al.
Publicado: (2020)

Intravitreal melphalan for persistent retinoblastoma vitreous seeds
por: Redondo-Villanueva, Marie Jeazelle H., et al.
Publicado: (2022)

Toxicity to intravitreal melphalan in a patient with retinoblastoma
por: Solaz-Ruiz, Marta Gema, et al.
Publicado: (2023)

Systemic Reactive Amyloidosis Associated with Castleman's Disease
por: Gaduputi, Vinaya, et al.
Publicado: (2013)

Secondary Amyloidosis Associated with Multiple Sclerosis
por: Kang, Seok Jae, et al.
Publicado: (2009)

Prophylactic antiemetic effects in gynecologic patients receiving fentanyl IV-patient controlled analgesia: comparison of combined treatment with ondansetron and dexamethasone with metoclopramide and dexamethasone
por: Jee, Young Seok, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_okaekjpiv4ul5e8sb1inonjf74